Saturday 17 October 2026 Export KRRO’s income statement to Excel — free account

Korro Bio, Inc.

Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.53 0.78 −8.38%

Follow KRRO

Alert me

Market cap: $137.1M
P/E: 0.0×
Fwd P/E: −2.0×
Dividend yield: —
F-score: n/a
Altman Z: −6.75
Beneish M: −3.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 20.79

Total sells 5.70

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	10	—	—	—	—	1	—	—
Sell	—	—	—	—	—	—	2	5	1	4	3	—

Insider Ownership 41.71%

Capital & Financial Ratios $m

Market Cap 137.09

Revenue 6.39

Net Income (106.64)

Free Cash Flow (68.26)

Net Debt (115.04)

Current Ratio 9.55

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.98)

P/S ratio 23.51

P/B ratio 1.46

Past 5Y EPS Growth —

This Y EPS Growth 57.40%

Next Y EPS Growth 8.16%

Next Y revenue growth (94.13%)

Next 5Y EPS Growth 30.71%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 86.10%

10-year low 10-year high

P/B against its own 10 years 49.30%

10-year low 10-year high

EV/Sales against its own 10 years 59.12%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	166	126	75	115
Receivables	—	2	1	—
Inventory	—	—	—	—
Other	4	—	—	—
	173	132	82	121

	2023	2024	2025	Q'26
Payables	7	4	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	19	15	12	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(44.30%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(23.20%)	(7.42%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	3	1	1	1	6
’24	—	—	—	—	2
’21	5	9	—	—	14
’20	7	9	11	10	37

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(17)	—	—	—
’25	(24)	(19)	(17)	(18)	(79)
’24	(22)	(15)	(16)	(7)	(60)
’23	(20)	(15)	(12)	(21)	(67)
’22	(17)	(13)	(12)	(11)	(54)
’21	(25)	(18)	(15)	(18)	(76)
’20	(9)	(10)	(11)	(15)	(45)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(17)	—	—	—
’25	(25)	(19)	(17)	(18)	(79)
’24	(28)	(21)	(21)	(9)	(78)
’23	(21)	(19)	(12)	(23)	(75)
’22	(17)	(13)	(12)	(16)	(59)
’21	(26)	(20)	(15)	(18)	(79)
’20	(10)	(11)	(12)	(19)	(52)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.69)	(1.07)	—	—	—
’25	(2.49)	(2.74)	(1.92)	(5.32)	(12.48)
’24	(2.44)	(2.43)	(2.26)	(2.26)	(9.37)
’23	(72.08)	(63.95)	(65.11)	148.05	(53.08)
’22	(33.50)	(30.50)	(27.50)	(24.50)	(227.58)
’21	(30.00)	(26.00)	(36.50)	(31.00)	(123.50)
’20	(8.00)	(9.50)	(8.00)	(15.00)	(41.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	558.50	725.00	234.00	50.00	9.15	30.01	5.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	1,024.50	2,144.55	2,918.50	289.50	279.50	98.00	55.89
People
People	Employees	—	—	39	47	87	74	48	101	104	58
	Revenue/emp, $m	—	—	0.00	0.62	0.43	0.19	0.00	0.00	0.02	0.11
Income, $m
Income, $m	Revenue	—	—	—	29	37	14	—	—	2	6
	Gross margin, %	—	0.00	0.00	100.00	100.00	100.00	0.00	—	100.00	100.00
	EBT	—	(20)	(19)	(19)	(26)	(85)	(58)	(81)	(83)	(117)
	EBT margin, %	—	0.00	0.00	(64.76)	(71.59)	(601.87)	0.00	0.00	(3,674.15)	(1,824.52)
	Net income	—	(20)	(19)	(19)	(27)	(85)	(58)	(81)	(84)	(117)
	Depreciation	—	1	1	1	1	3	2	4	2	4
Per share, $
Per share, $	Revenue	—	0.00	0.00	167.32	57.33	20.48	0.00	0.00	0.25	0.68
	Earnings	—	(1,439.33)	(626.41)	(114.50)	(41.00)	(123.50)	(227.58)	(53.08)	(9.37)	(12.48)
	Cash flow	—	(1,036.45)	(556.34)	197.78	(70.05)	(110.71)	(210.37)	(44.00)	(6.73)	(8.36)
	Capex	—	(132.13)	(14.25)	(6.15)	(10.34)	(4.24)	(20.14)	(5.12)	(2.01)	(0.06)
	Free cash flow	—	(1,168.58)	(570.59)	191.63	(80.39)	(114.95)	(230.51)	(49.13)	(8.74)	(8.42)
	Book value	—	0.00	1,321.11	967.39	298.39	190.43	254.24	111.13	17.98	5.48
	Shares, m	—	0	0	0	1	1	0	2	9	9
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	—	—	0.00	0.00
	P/S	—	—	—	0.00	30.75	5.00	—	—	9.63	11.77
	P/B	—	—	—	0.91	5.91	1.35	—	—	2.12	1.46
	EV/Sales	—	—	—	0.00	25.21	1.72	—	—	6.57	2.88
	EV/FCF	—	—	—	(1.98)	(17.98)	(0.77)	—	—	(2.97)	(0.23)
Cash, $m
Cash, $m	Operating cash flow	—	(15)	(17)	34	(45)	(76)	(54)	(67)	(60)	(79)
	Capex	—	(2)	0	(1)	(7)	(3)	(5)	(8)	(18)	(1)
	Free cash flow	—	(16)	(17)	33	(52)	(79)	(59)	(75)	(78)	(79)
Balance, $m
Balance, $m	Working capital	—	16	39	169	198	123	48	153	117	70
	Total debt	—	47	85	—	15	15	14	—	—	—
	Net debt	—	29	43	(217)	(205)	(116)	(55)	(166)	(126)	(75)
	Shareholders’ equity	—	—	40	167	192	131	65	170	160	51
Returns, %
Returns, %	ROA	—	(90.85)	(86.06)	(14.79)	(10.87)	(37.63)	(44.80)	(54.96)	(37.32)	(69.03)
	ROIC	—	(35.44)	(14.24)	0.00	0.00	(347.42)	(384.74)	(1,404.78)	(167.38)	0.00
	ROE	—	54.58	51.70	(32.23)	(14.73)	(52.39)	(365.06)	(229.04)	(50.61)	(110.70)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MOLN Molecular Partners AG Sponsored ADR	$143.5M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+23.77% (above 0%: growing)	0.00%	0.00%	Compare
TARA Protara Therapeutics, Inc.	$141.8M	— (loss-making)	—	—	n/m	−28.10% (below 0%: shrinking)	0.00%	0.00%	Compare
ALXO ALX Oncology Holdings Inc.	$138.3M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+31.65% (above 0%: growing)	0.00%	0.00%	Compare
NKTX Nkarta, Inc.	$138.2M	— (loss-making)	—	—	n/m	−29.19% (below 0%: shrinking)	0.00%	0.00%	Compare
AVXL Anavex Life Sciences Corp.	$137.2M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%	Compare
KRRO Korro Bio, Inc.	$137.1M	— (loss-making)	— (loss-making)	−86.28% (below 0%: shrinking)	n/m	+12.07% (above 0%: growing)	100.00%	0.00%
ANTX AN2 Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	+7.91% (above 0%: growing)	0.00%	0.00%	Compare
CUE Cue Biopharma, Inc.	$135.6M	— (loss-making)	— (loss-making)	+166.66% (above 0%: growing)	n/m	−742.65% (below 0%: shrinking)	100.00%	(1,113.30%)	Compare
TLSA Tiziana Life Sciences Ltd	$134.7M	— (loss-making)	—	—	−258.11% (below 0%: shrinking)	+18.03% (above 0%: growing)	0.00%	—	Compare
Median of peers	$137.7M	—	—	−98.86%	—	+12.97%	0.00%	0.00%

All 614 Biotechnology stocks →

Korro Bio, Inc. (KRRO) key facts

Strength: Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024.
Korro Bio, Inc. (KRRO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KRRO traded at $8.53, a market capitalization of $137.1 million.
Return on equity was −110.7% and debt-to-equity 0.00.
Its Altman Z-score is −6.75 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.